J B Chemicals AND Pharmaceuticals Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: J B Chemicals AND Pharmaceuticals Limited Pharmaceutical Export Portfolio Dataset — 20 Products, $47.9M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

J B Chemicals AND Pharmaceuticals Limited — Pharmaceutical Exporter Profile (2026) | 20 Products, $47.9M Trade | TransData Nexus

J B Chemicals AND Pharmaceuticals Limited

Indian Pharmaceutical Exporter · Antihistamines & Allergy Specialist · $47.9M Total Trade · DGFT Verified

J B Chemicals AND Pharmaceuticals Limited is an Indian pharmaceutical exporter with a total trade value of $47.9M across 20 products in 12 therapeutic categories. Based on 2,830 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Cetirizine ($7.5M), Metronidazole ($7.3M), Ciprofloxacin ($5.3M).

J B Chemicals AND Pharmaceuticals Limited — Export Portfolio & Destination Treemap

J B Chemicals AND Pharmaceuticals Limited pharmaceutical export portfolio — 20 products across 12 therapeutic categories. Source: Indian Customs (DGFT).

Who is J B Chemicals AND Pharmaceuticals Limited? — Company Overview & Market Position

J B Chemicals & Pharmaceuticals Limited (JBCPL) is a prominent Indian pharmaceutical company established on December 18, 1976, in Mumbai, Maharashtra. The company specializes in the manufacture and marketing of pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (APIs) both domestically and internationally. JBCPL is publicly listed on the Bombay Stock Exchange (BSE) under the ticker symbol 506943 and on the National Stock Exchange (NSE) with the symbol JBCHEPHARM.

As of the fiscal year 2024, JBCPL reported a total revenue of ₹3,333.32 crore and a net worth of ₹2,886.26 crore. The company employs approximately 5,984 professionals across its operations. The authorized share capital stands at ₹20.30 crore, with a paid-up capital of ₹15.67 crore. The registered office is located at Neelam Centre B Wing, 4th Floor, Hind Cycle Road, Worli, Mumbai, Maharashtra, 400030.

What Does J B Chemicals AND Pharmaceuticals Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Cetirizine$7.5M 2

Product Portfolio — Top 20 by Export Value

J B Chemicals AND Pharmaceuticals Limited exports 20 pharmaceutical products across 12 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Cetirizine	Antihistamines & Allergy	$7.5M	172	4.2%	7
2	Metronidazole	Advanced Antibiotics	$7.3M	517	3.6%	4
3	Ciprofloxacin	Antibiotics	$5.3M	196	1.8%	9
4	Enalapril	Cardiovascular	$4.8M	361	2.0%	3
5	Caffeine	Respiratory & OTC	$4.6M	519	4.2%	4
6	Vitamin	Nutritional Supplements	$3.8M	237	2.7%	5
7	Atenolol	Cardiovascular	$3.4M	164	8.5%	5
8	Loratadine	Antihistamines & Allergy	$2.6M	70	1.5%	8
9	Nifedipine	Cardiovascular	$2.4M	125	7.9%	4
10	Aspirin	Analgesics & Antipyretics	$1.7M	93	4.5%	6
11	Bromhexine	Respiratory & OTC	$907.7K	48	5.6%	4
12	Fexofenadine	Antihistamines & Allergy	$800.0K	16	0.7%	13
13	Extract	Ayurvedic & Herbal Products	$625.8K	101	5.2%	6
14	Herbal	Ayurvedic & Herbal Products	$578.7K	25	3.1%	5
15	Mebendazole	Antimalarial & Antiparasitic	$539.7K	94	3.9%	4
16	Tinidazole	Advanced Antibiotics	$301.0K	15	1.6%	11
17	Codeine	Analgesics & Antipyretics	$257.3K	18	0.2%	11
18	Lorazepam	CNS & Psychiatric	$156.3K	19	6.2%	5
19	Prednisone	Respiratory	$114.7K	16	0.4%	8
20	Nicotine	Other	$111.8K	24	0.7%	5

J B Chemicals AND Pharmaceuticals Limited exports 20 pharmaceutical products across 12 therapeutic categories with a total export value of $47.9M. The top category is Antihistamines & Allergy (22.9% of portfolio), followed by Cardiovascular (22.2%), indicating a concentrated portfolio with the top 5 products accounting for 61.7% of total export value.

J B Chemicals AND Pharmaceuticals Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

JBCPL operates multiple manufacturing facilities across India, including locations in Thane, Belapur, Ankleshwar, Panoli, and Daman. The bulk drug plant at Panoli and the formulation plant at Daman became operational in April 1995. These facilities are equipped with state-of-the-art technology and adhere to stringent quality control measures to ensure the production of high-quality pharmaceutical products.

3Key Leadership

The leadership team at JBCPL is headed by Chief Executive Officer (CEO) Nikhil Ashokkumar Chopra, who has been with the company since October 2020. Other key executives include Sumit Bose, Non-Executive & Independent Director since 2020, and Gaurav Trehan, Non-Executive Director since 2021. The board also comprises directors such as Richa Arora, appointed in July 2025, and Ashwani Kumar Puri, appointed in May 2025.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does J B Chemicals AND Pharmaceuticals Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

JBCPL has established a significant presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained approvals for various pharmaceutical formulations, enabling it to market its products in these regions. For instance, JBCPL has received approvals for its formulations from the U.S. Food and Drug Administration (FDA), allowing it to supply products to the U.S. market. Similarly, the company has secured European Medicines Agency (EMA) approvals for certain products, facilitating its entry into the European market. These regulatory approvals underscore JBCPL's commitment to meeting international quality standards and expanding its global footprint.

2Emerging Markets

JBCPL has strategically expanded its presence in emerging markets, including regions in Africa, Latin America, and Southeast Asia. The company's adherence to World Health Organization (WHO) prequalification standards has been instrumental in gaining access to these markets. By obtaining WHO prequalification, JBCPL ensures that its products meet international quality benchmarks, thereby enhancing their acceptance in these regions. This strategic approach has enabled JBCPL to tap into high-growth markets and diversify its revenue streams.

Geographic Strategy

J B Chemicals AND Pharmaceuticals Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

JBCPL has achieved significant milestones in the U.S. market, including the registration of its manufacturing facilities with the U.S. Food and Drug Administration (FDA). The company has also received approvals for several Abbreviated New Drug Applications (ANDAs), allowing it to market generic formulations in the U.S. Additionally, JBCPL has filed Drug Master Files (DMFs) with the FDA, providing detailed information about its manufacturing processes and quality control measures. The company's facilities have undergone FDA inspections, and there are no records of Form 483 observations, warning letters, or import alerts, indicating a strong compliance history.

2WHO & EU GMP

JBCPL's commitment to quality is demonstrated by its adherence to Good Manufacturing Practices (GMP) standards. The company has obtained WHO prequalification for certain products, ensuring they meet international quality standards. Additionally, JBCPL holds EU GMP certificates, affirming its compliance with European manufacturing standards. These certifications enhance the company's credibility and facilitate market access in various international regions.

3CDSCO & Indian Regulatory

J B Chemicals AND Pharmaceuticals Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

JBCPL operates in a competitive landscape with several key players in the pharmaceutical industry. In the antihistamines and allergy segment, the company faces competition from other established pharmaceutical firms. In the cardiovascular category, JBCPL competes with companies offering similar formulations. The advanced antibiotics segment also has multiple competitors providing comparable products. Despite this competition, JBCPL has managed to secure a significant market share in these categories, indicating its strong position in the market.

2Key Differentiators

JBCPL's key differentiators include its diverse product portfolio, which spans various therapeutic areas such as antihistamines, cardiovascular, and advanced antibiotics. The company's commitment to quality is evident through its adherence to international standards, including WHO prequalification and EU GMP certifications. Additionally, JBCPL's strategic focus on both regulated and emerging markets allows it to leverage growth opportunities across different geographies. These factors collectively contribute to the company's competitive advantage in the pharmaceutical industry.

3Strategic Position

Buyer Due Diligence Brief — Evaluating J B Chemicals AND Pharmaceuticals Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

JBCPL has a strong track record in the pharmaceutical industry, with a consistent export volume of $47.9 million USD over 2,830 shipments. The company exports 20 products across 12 therapeutic categories, demonstrating its diverse product range. The top five products—Cetirizine, Metronidazole, Ciprofloxacin, Enalapril, and Caffeine—account for 61.7% of the total export value, indicating a focused yet diversified portfolio. JBCPL's adherence to international quality standards and regulatory compliance further underscores its reliability as a supplier.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

FDA Approval: Confirm that the product is listed in the FDA's Orange Book, indicating approval for marketing in the U.S.

WHO-GMP Certification: Check for WHO prequalification status, which ensures adherence to international manufacturing standards.

Frequently Asked Questions — J B Chemicals AND Pharmaceuticals Limited

How many pharmaceutical products does J B Chemicals AND Pharmaceuticals Limited export from India?

J B Chemicals AND Pharmaceuticals Limited exports 20 pharmaceutical products across 12 therapeutic categories. The top exports are Cetirizine ($7.5M), Metronidazole ($7.3M), Ciprofloxacin ($5.3M), Enalapril ($4.8M), Caffeine ($4.6M). Total export value is $47.9M.

What is J B Chemicals AND Pharmaceuticals Limited's total pharmaceutical export value?

J B Chemicals AND Pharmaceuticals Limited's total pharmaceutical export value is $47.9M, based on 2,830 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does J B Chemicals AND Pharmaceuticals Limited cover?

J B Chemicals AND Pharmaceuticals Limited exports across 12 therapeutic categories. The largest are Antihistamines & Allergy (22.9%, 3 products), Cardiovascular (22.2%, 3 products), Advanced Antibiotics (15.9%, 2 products).

Get Full J B Chemicals AND Pharmaceuticals Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.